title: Mucosal inflammation in spondylarthritides: past, present, and future.
abstract: Spondylarthritides (SpA) and inflammatory bowel disease (IBD) are idiopathic, chronic inflammatory disorders. Although they are very distinct and well-defined entities, there is clinical and genetic evidence supporting some degree of overlap between the pathogenesis of the two. Subclinical gut inflammation is present in up to two thirds of all SpA patients and can evolve into IBD. This subclinical gut inflammation has been shown to be strongly associated with joint inflammation, providing a clue for a common pathophysiologic background. Despite extensive research progress in the field over the past few years, many questions remain unanswered. In this paper, we focus on the clinical, genetic, and pathophysiologic overlap of SpA and IBD. Furthermore, we discuss some of the targets that may influence therapeutic decision making.
authors: Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 0K12-IB, 9000 Ghent, Belgium. liesbet.vanpraet@ugent.be
authors: Liesbet
authors: L
authors: Van Praet
authors: Filip
authors: F
authors: Van den Bosch
authors: Herman
authors: H
authors: Mielants
authors: Dirk
authors: D
authors: Elewaut
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000473:pathology*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D025241:Spondylarthritis / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015415:Biomarkers; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha